EVGN Stock Forecast 2025-2026
Distance to EVGN Price Targets
EVGN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Evogene (EVGN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on EVGN and similar high-potential opportunities.
Latest EVGN Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, EVGN has a bullish consensus with a median price target of $5.50 (ranging from $5.00 to $6.00). Currently trading at $0.97, the median forecast implies a 467.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EVGN Analyst Ratings
EVGN Price Target Range
Latest EVGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EVGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 23, 2024 | Lake Street | Ben Klieve | Buy | Maintains | $12.00 |
| Oct 2, 2023 | Alliance Global Partners | Ben Haynor | Buy | Initiates | $1.85 |
| Aug 18, 2023 | Lake Street | Ben Klieve | Buy | Maintains | $3.00 |
| Jul 21, 2023 | Roth MKM | Buy | Maintains | $0.00 | |
| May 2, 2023 | Lake Street | Ben Klieve | Buy | Initiates | $2.00 |
| Sep 12, 2022 | Aegis Capital | Nathan Weinstein | Buy | Maintains | $8.00 |
| Sep 2, 2022 | Roth MKM | Buy | Maintains | $0.00 | |
| Oct 8, 2021 | Roth Capital | Brian Wright | Buy | Initiates | $7.00 |
| Jul 29, 2021 | Aegis Capital | Buy | Initiates | $0.00 | |
| Dec 1, 2020 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
| Nov 12, 2014 | Credit Suisse | Outperform | Maintains | $22.00 | |
| Dec 17, 2013 | Deutsche Bank | Buy | Initiates | $0.00 | |
| Dec 16, 2013 | Credit Suisse | Outperform | Initiates | $0.00 |
Evogene Ltd. (EVGN) Competitors
The following stocks are similar to Evogene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Evogene Ltd. (EVGN) Financial Data
Evogene Ltd. has a market capitalization of $6.88M with a P/E ratio of 0.3x. The company generates $8.51M in trailing twelve-month revenue with a -193.7% profit margin.
Revenue growth is +178.7% quarter-over-quarter, while maintaining an operating margin of -314.5% and return on equity of -83.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Evogene Ltd. (EVGN) Business Model
About Evogene Ltd.
Develops innovative biotechnology solutions for various industries.
Evogene leverages its computational predictive biology platform to create products that enhance efficiency in agriculture, pharmaceuticals, and industrial applications. The company collaborates with leading firms to commercialize its discoveries, generating revenue through partnerships and product sales.
Headquartered in Rehovot, Israel, Evogene is positioned as a key player in the biotechnology sector, focusing on traits that improve crop yield, resistance, and sustainability, thus addressing critical challenges in health and industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
117
CEO
Mr. Ofer Haviv CPA
Country
Israel
IPO Year
2010
Website
www.evogene.comEvogene Ltd. (EVGN) Latest News & Analysis
Evogene Ltd. (NASDAQ:EVGN) will hold its Q4 2024 earnings conference call on March 6, 2025, at 9:00 AM ET, featuring key executives including the CEO and CFO.
Evogene's Q4 earnings call highlights financial performance and strategic direction, potentially impacting stock valuation and investor sentiment. Key updates can influence market reactions.
On March 6, 2025, a conference call announced that total revenues for 2024 were about $8.5 million, up from $5.6 million in 2023, driven by AgPlenus' collaboration with Bayer and Casterra's seed sales.
Revenue growth from $5.6M to $8.5M indicates strong business performance, driven by collaborations and sales, potentially boosting investor confidence and share value.
Nir Nirmodi will replace Sarit Firon as CEO of Evogene Ltd., while Firon remains a board member.
Management changes can impact a company's strategy and performance. Mr. Nirmodi's appointment may signal a shift in direction, affecting investor confidence and stock performance.
Evogene Ltd. (Nasdaq: EVGN) will release its Q4 2024 financial results on March 6, 2025, at 9:00 AM ET. A conference call will follow the announcement.
The scheduled earnings release may impact Evogene Ltd.'s stock price and investor sentiment, reflecting the company's financial health and growth potential in the life sciences sector.
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
2 months agoAgPlenus Ltd. has identified initial fungicidally active compounds, advancing its development of sustainable crop protection products as a subsidiary of Evogene Ltd.
AgPlenus's discovery of new fungicidal compounds signals potential growth in sustainable agriculture, which could enhance market competitiveness and profitability for investors in the sector.
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
4 months agoEvogene Ltd. (NASDAQ:EVGN) will hold its Q3 2024 earnings conference call on November 21, 2024, at 9:00 AM ET, featuring CEO Ofer Haviv and CFO Yaron Eldad.
Evogene's Q3 earnings call may reveal financial performance and strategic insights, impacting stock valuation and investor sentiment in the biotech sector.
Frequently Asked Questions About EVGN Stock
What is Evogene Ltd.'s (EVGN) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Evogene Ltd. (EVGN) has a median price target of $5.50. The highest price target is $6.00 and the lowest is $5.00.
Is EVGN stock a good investment in 2025?
According to current analyst ratings, EVGN has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EVGN stock?
Wall Street analysts predict EVGN stock could reach $5.50 in the next 12 months. This represents a 467.0% increase from the current price of $0.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Evogene Ltd.'s business model?
Evogene leverages its computational predictive biology platform to create products that enhance efficiency in agriculture, pharmaceuticals, and industrial applications. The company collaborates with leading firms to commercialize its discoveries, generating revenue through partnerships and product sales.
What is the highest forecasted price for EVGN Evogene Ltd.?
The highest price target for EVGN is $6.00 from at , which represents a 518.6% increase from the current price of $0.97.
What is the lowest forecasted price for EVGN Evogene Ltd.?
The lowest price target for EVGN is $5.00 from at , which represents a 415.5% increase from the current price of $0.97.
What is the overall EVGN consensus from analysts for Evogene Ltd.?
The overall analyst consensus for EVGN is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.50.
How accurate are EVGN stock price projections?
Stock price projections, including those for Evogene Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.